Brigatinib (BRG) vs crizotinib (CRZ) in patients (Pts) with ALK inhibitor-naive advanced ALK plus NSCLC from ALTA-1L
Authors
Yang, JCHKim, HR
Ahn, MJ
Han, JY
Hochmair, MJ
Lee, KH
Delmonte, A
Campelo, MRG
Kim, DW
Felip, E
Califano, Raffaele
Spira, A
Gettinger, S
Tiseo, M
Haney, J
Kerstein, D
Popat, S
Camidge, DR
Affiliation
National Taiwan University Hospital, TaiwanIssue Date
2019
Metadata
Show full item recordCitation
Yang JCH, Kim HR, Ahn M-J, Han J-Y, Hochmair MJ, Lee KH, et al. O1-4-2 [Encore]Brigatinib (BRG) vs Crizotinib (CRZ) in Patients (Pts) With ALK Inhibitor-Naive Advanced ALK+ NSCLC from ALTA-1L. Annals of Oncology. 2019;30(Supplement_6).Journal
Annals of OncologyDOI
10.1093/annonc/mdz339.006Additional Links
https://dx.doi.org/10.1093/annonc/mdz339.006Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdz339.006